RECRUITING
I'm interested ...!!
Molecular Signatures of Cutaneous Dupilumab Response
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Conditions:
🦠 Atopic Dermatitis
🗓️ Study Start (Actual) 1 February 2023
🗓️ Primary Completion (Estimated) 1 February 2026
✅ Study Completion (Estimated) 1 February 2026
👥 Enrollment (Estimated) 15
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 San Francisco, California, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • 1. 18 years of age or older
    • 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7

    Exclusion Criteria:

    • 1. Known pregnancy
    • 2. Known immunodeficiencies
    • 3. Known parasitic infection -
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 4 May 2023
  • First Submitted that Met QC Criteria 4 May 2023
  • First Posted 15 May 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 25 June 2024
  • Last Update Posted 27 June 2024
  • Last Verified June 2024
I'm interested ...!!